Departments and specialties
Mayo Clinic has one of the largest and most experienced practices in the United States,
with campuses in Arizona, Florida and Minnesota. Staff skilled in dozens of specialties work
together to ensure quality care and successful recovery.
Departments that treat this condition
The Mayo Nephrology Collaborative Group (MNCG) develops and conducts studies of renal parenchymal diseases, including membranous nephropathy. The MNCG is a consortium of nephrologists from Mayo Clinic campuses in Minnesota, Florida and Arizona and from other centers across the United States.
Mayo Clinic has conducted pioneer clinical studies evaluating the use and effectiveness of rituximab (Rituxan) in treating membranous nephropathy. Mayo researchers are also studying the role of a variety of antibodies in membranous nephropathy.
Mayo has also evaluated the use and safety of adrenocorticotropic hormone (ACTH) in the treatment of membranous nephropathy. A 2016 study on the use of ACTH studies by Mayo researchers found that the hormone effectively lowered urine protein levels in people with the disease who didn't get better with oral corticosteroids, and it did so with few side effects.
See a list of publications on membranous nephropathy by Mayo doctors on PubMed.